---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-001194"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:06:43.609107+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ADMA raises FY2024-25 revenue guidance; preliminary Q4 rev $72-74M, FY rev $256-258M

## Summary
- Q4 2023 preliminary revenue $72-74M; full year $256-258M.
- FY2024 revenue guidance raised to >$320M from $290M; FY2025 to >$370M from $335M.
- FY2024 net income expected >$60M (from $55M) and adjusted EBITDA ~$85M.
- New growth: manufacturing yield enhancement and S. pneumonia hyperimmune globulin (potential peak revenue $300-500M).
- ASCENIV label expansion via pediatric study progressing.

## SEC filing metadata
- accession: 0001140361-24-001194
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036124001194/0001140361-24-001194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036124001194/ef20018240_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-001194
- JSON: https://secwatch.observer/filing/0001140361-24-001194.json
- Plain text: https://secwatch.observer/filing/0001140361-24-001194.txt

## Key facts
- Earnings Releases
  ADMA BIOLOGICS, INC. reported fourth quarter and full year 2023 results: revenue $72-74 Million. Guidance raised.
  - Period: fourth quarter and full year 2023
  - Revenue: $72-74 Million
  - Guidance: raised
  - Result: preliminary results
  source text: ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update 4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036124001194/0001140361-24-001194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.